Experimental section -Chemistry
Chemicals, materials and methods.
All the commercial available reagents and solvents were used as purchased from vendors without further purification. Dry solvents (THF, Et 2 O, CH 2 Cl 2 , DMF, DMSO, MeOH) were purchased from Sigma-Aldrich. Automated column chromatography purifications were performed using a Teledyne ISCO apparatus (CombiFlash® Rf) with pre-packed silica gel columns of different sizes (from 4 g up to 120 g). Mixtures of increasing polarity of cyclohexane (Cy) and ethyl acetate (EtOAc) or cyclohexane and methyl tert-butyl ether (MTBE) were used as eluents. NMR experiments were run on a Bruker Avance III 400 system (400.13 MHz for 1 H, and 100.62 MHz for 13 C), equipped with a BBI probe and Z-gradients.
Spectra were acquired at 300 K, using deuterated dimethylsulfoxide (DMSO-d 6 ) or chloroform (CDCl 3 ) as solvents. UPLC/MS analyses were run on a Waters ACQUITY UPLC/MS system consisting of a SQD (single quadrupole detector) mass spectrometer equipped with an electrospray ionization interface and a photodiode array detector. The PDA range was 210-400 nm. Analyses were performed on an ACQUITY UPLC BEH C 18 column (100 x 2.1mmID, particle size 1.7 mm) with a VanGuard BEH C 18 precolumn (5 x 2.1 mmID, particle size 1.7 mm). Mobile phase was 10 mM NH 4 OAc in H 2 O at pH 5 adjusted with CH 3 COOH (A) and 10 mM NH 4 OAc in CH 3 CN-H 2 O (95:5) at pH 5.0. Electrospray ionization in positive and negative mode was applied. Purifications by preparative HPLC/MS were run on a Waters Autopurification system consisting of a 3100 single quadrupole mass spectrometer equipped with an Electrospray Ionization interface and a 2998 Photodiode Array Detector. HPLC system included a 2747 sample manager, 2545 binary gradient module, system fluidic organizer and 515 HPLC pump. PDA range was 210-400 nm. Purifications were performed on a XBridge™ Prep C 18 OBD column (100 x 19 mmID, particle size 5 mm) with a XBridge™Prep C 18 (10 x 19 mmID, particle size 5 mm) guard cartridge. Mobile phase was 10 mM NH 4 OAc in MeCN-H 2 O (95:5) at pH 5. Electrospray ionization in positive and negative mode was used. Optical rotations were measured on a Propol automatic polarimeter using a sodium lamp (589 nm) as the light source, using CHCl 3 as a solvent and a 1 dm cell.
Synthesis of Activity Based Probes (3-4) and inhibitors of NAAA (1-2 and 5-7).
Compounds 1 (CC-ABP) 1 , 2 (ARN726) 2 , 5 3 , 6 3 and 7 4 were synthesized according to described procedures and their spectroscopic data are in agreement with those previously reported. Compound S1 was synthesized according to a previously reported procedure. 3 Step
BODIPY-ABP. 5-(4-(4-
(
tert-butyl ((2S,3S)-2-methyl-1-(4-(methylsulfonyl)phenoxy)-4-oxoazetidin-3-yl)carbamate (8)
A solution of benzyl derivative S1 (0.837 g, 2.85 mmol) in absolute EtOH (40.0 mL) was submitted to ten cycles of vacuum and argon. Subsequently cyclohexadiene (2.69 mL, 28.5 mmol) and palladium on activated charcoal (0.837 g) were added to the solution and three more cycles of vacuum and argon were performed. General procedure (G1) for chloroformate preparation.
To a stirred solution of triphosgene (0.4 equiv) in toluene (5 mL/mmol), pyridine (1.25 equiv) was added. After stirring for 1 h at 0 °C under argon, the alcohol was added dropwise. The mixture was stirred for 17 h at room temperature before being filtrated. The precipitate was rinsed twice with toluene and concentration of the filtrate under vacuum afforded crude chloroformate, which was directly used in the next step.
Step 2.
5-azidopentyl N-[(2S,3S)-2-methyl-1-(4-methylsulfonylphenoxy)-4-oxo-azetidin-3-yl]carbamate (9)
5-Azido 1-pentanol was synthesized according to described procedure 5 and its spectroscopic data are in agreement with those previously reported.
a) Pentyl azido chloroformate (S2).
S2 was obtained following the general procedure G1, employing pentyl azido alcohol (1.0 g, 7.74 mmol), triphosgene (0.918 g, 3.09 mmol), pyridine (0.778 mL, 9.67 mmol). The compound was used immediately after preparation. Step 3. Synthesis of BODIPY-ABP 3.
To a solution of 9 (0.012 g, 0.028 mmol) and BODIPY alkyne 5 Step
Synthesis of 5-(2-Bicyclo[2.2.1]hept-5-enylmethoxy)pentyl carbonochloridate (S7)
Intermediate S4 was synthesized following previous reported procedure and its spectroscopic data are comparable to the literature. 6 
a) (1S,4S)-5-(((5-(Trityloxy)pentyl)oxy)methyl)Bicyclo[2.2.1]hept-2-ene (S5)
To 
b) 5-((1S,4S)-Bicyclo[2.2.1]hep-5-e-2-ylmethoxy)pentan-1-ol (S6)
Step 2. 5-(Norbornan-2-ylmethoxy)pentyl N-[(2S,3S)-2-methyl-1-(4-methylsulfonylphenoxy)-

4-oxo-azetidin-3-yl]carbamate (4)
Under a nitrogen atmosphere, a solution of the intermediate -lactam tosylate salt (Scheme S1,
Step 2 (b) for the synthesis of 3) (0.070 g, 0.16 mmol) in dry CH 2 Cl 2 (3.0 mL) was treated with DIPEA (0.042 mL, 0. Finally, cells were washed six times with PBS and coverslips were mounted with DAPI (Thermo Fisher Scientific). Images were acquired using Nikon A1 confocal microscopy (Nikon) at the following wavelengths: 405 nm for DAPI, 490 for probe, and 640 for anti-NAAA.
Supplementary figures
Fig. S1
Fluorescence microscopy analysis of wild type HEK293, which were treated with probe 4 (1 M). Cells were fixed and incubated with an anti-NAAA antibody and an Alexa Fluor 647 secondary reagent (in red) followed by 5 M of tetrazine-BODIPY (in green). Nuclei were marked with DAPI (blue). Scale bar = 10 m.
